Pharmacologic targeting of Nedd8-activating enzyme reinvigorates T-cell responses in lymphoid neoplasia.
Journal Information
Full Title: Leukemia
Abbreviation: Leukemia
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"Competing interests AVD has received consulting fees from Abbvie, AstraZeneca, Bayer Oncology, BeiGene, Bristol Meyers Squibb, Genentech, GenMab, Incyte, Janssen, Lilly Oncology, Nurix, Oncovalent, Pharmacyclics and TG Therapeutics and has ongoing research funding from Abbvie, AstraZeneca, Bayer Oncology, Bristol Meyers Squibb, Cyclacel, MEI Pharma, Nurix and Takeda Oncology. PT has received consulting fees from ADC Therapeutics, Genentech and TG Therapeutics."
Funding Disclosure
Evidence found in paper:
"Funding Open access funding provided by SCELC, Statewide California Electronic Library Consortium."
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025